ABOUT US

Vertically Integrated Biologics Company

Our Mission

Simply put, our mission is to drive greater good.

At every level in our company, our singular focus is to deliver value through safe, effective and affordable biopharmaceuticals, starting with biosimilars targeting neutropenia, breast cancer, metastatic colorectal cancer and psoriasis. Not only will these medications provide critical, often life-saving benefit to patients at favorable cost, they will profit our shareholders, staff, and partner and payer communities as well. Our aim is to deliver end-to-end advantage, benefiting all stakeholders throughout our value chain.

Company Overview

In 1984, Dr. Allen Chao helped ignite a revolution in healthcare as a pioneer in the off-patent “generic” drug industry. As the founder and visionary of Watson Pharmaceuticals, he had a mission to drive down the cost of prescription drugs and extend their availability to millions of patients who otherwise couldn’t afford the medications they needed. In just ten years, from 2005 -2014, generics are estimated to have saved our healthcare system over $1.68 Trillion* – more than $3 Billion a week.

*Generic Drug Savings in the U.S., 2015 Edition, Generic Pharmaceutical Association

More than thirty years later, the revolution continues at Tanvex BioPharma. Here, Dr. Chao and his dedicated and talented team are applying the same passion, experience and expertise for improving the availability and affordability of pharmaceuticals to a new generation of drugs: biopharmaceuticals, including biologics and their non-branded, off-patent drug equivalents, biosimilars.

Producing biologics and biosimilars in sufficiently large quantities, while maintaining quality and consistency, is a complex challenge that has contributed to their high cost. Today, through more efficient in-house, end-to-end manufacturing and innovative, patent-pending processes, Tanvex BioPharma is revolutionizing the biopharmaceutical industry. We offer a truly, fully vertically integrated manufacturing platform for biopharmaceuticals. By controlling the entire process from R&D and cell-line development, Tanvex BioPharma can achieve enviable quality and consistency, and respond with unparalleled agility to rapidly changing market and regulatory demands.

Tanvex BioPharma is at the forefront of this emerging industry, poised to repeat the success of Dr. Chao’s first company, Watson Pharmaceuticals, this time revolutionizing the biopharmaceutical space by developing and delivering safe, effective, and affordable biologic and biosimilar drugs to the people whose lives depend upon them.

As a global business, Tanvex BioPharma has successfully united operating teams in Taiwan and the United States, a strategy that provides efficiencies, scale, and multi-faceted scientific thinking.

Our Approach

From the outset, our approach has been strategic: Build a company that can sustain itself over time; execute with agility and persistence; quickly respond to regulatory changes and opportunity; attract, nurture and grow stellar talent; respect the environment; and create and deliver value to every stakeholder.

Our culture prizes creative thinking and innovation in pursuit of continuous improvement and excellence. Our multi-product facility meets stringent global regulatory requirements and utilizes the latest “green” technologies, affording maximum flexibility, rapid turnaround times, and reduced cost and time to market. Purpose-built, our infrastructure supports the company’s microbial and mammalian cell line development, process development, and Current Good Manufacturing Practice (cGMP) capabilities.

The Value of Vertical Integration

Tanvex BioPharma is a vertically integrated company, with end-to-end capabilities from R&D through to commercialization, well funded and unencumbered by partnership or contractual agreements that can create drag or inertia.

Mammalian and microbial cell line development and characterization, master cell selection and cell “seeds” are produced in the company’s Taiwan-based lab.

Second generation upstream development takes place in the U.S. facility, where working cell banks are grown and reproduced in quantity, and monitored for stability, expression level, and the physical and biologic properties most similar to the reference products, preparatory to harvest. Investments in high-volume production facilities, microbial fermenters and mammalian bioreactors ensure the ability to scale quickly for product commercialization.

Downstream activities including purification and packaging take place in-house in the U.S. plant. The facility also incorporates warehouse space for storage of product prior to distribution.

Combined with its executional model, this gives Tanvex BioPharma unprecedented self-reliance, control and flexibility, for a unique competitive advantage.

Board of Directors

Dr. Allen Chao, Founder, Honorary Chairman of the Board of Directors
  • Current Key Positions

    Board Director, Tanvex BioPharma, Inc.

    Board Director, Tanvex Biologics Corporation

    Board Director, Tanvex Biologics, Inc.

    Board Director, Ansun BioPharma, Inc.

    Board Director, Mithra Biotechnology Inc.

    Trustee, Taipei Medical University

  • Previous Experiences

    Chairman, Watson Pharmaceuticals, Inc. (2008)

    CEO, Watson Pharmaceuticals, Inc. (1984~2007)

Dr. Henry Chen, Chairman
  • Current Key Positions

    Board Director, Tanvex BioPharma, Inc.

    Founder and Managing Partner at Delos Capital

    Co-founder at ReNiva Medical

    Co-founder at Curamir Therapeutics Inc

    Co-founder at Tulavi Therapeutics

  • Previous Experiences

    Partner and Co-Head of Asia, Permira

    Managing Director, Investment Banking, Goldman Sachs Asia

    Corporate finance lawyer, Davis Polk in New York and Hong Kong

    Juris Doctorate degree from Harvard Law School

    Bachelor and Master’s degrees from Harvard University

Dr. David Hsia, Director of the Board
  • Current Key Positions

    Board Director, Tanvex BioPharma, Inc.

    Advisor, Advisory Committee of Allianz Pharmascience Ltd.

  • Previous Experiences

    Senior Vice President, R&D, Watson Pharmaceuticals, Inc. (1990~2008)

    Vice President, R&D, Watson Pharmaceuticals, Inc. (1984~1990)

Mr. Chen, Chi-Chuan, Director of the Board
  • Current Key Positions

    Board Director, Tanvex BioPharma, Inc.

    Vice General Manager, Investment Management and Special Assistant to Chairman of Ruentex Group

    Representative of corporate Board director, TaiMed Biologics, Inc.

    Representative of Corporate Board Director, OBI Pharma, Inc.

    Representative of Corporate Board Director, Amaran Biotechnology, Inc.

    Representative of Corporate Board Director, Diamond BioFund

    Representative of Corporate Board Director, Diamond Capital Inc.

    Representative of Corporate Board Director, Sinew Pharma

    Representative of Corporate Board Director, CHO Pharma, Inc.

    Representative of Corporate Board Director, Cotton Field Organic Co.,Ltd

    Board director, Mr. Hsun-Ruo Yin Educational Foundation

    Partner, Delos Capital Fund, LP

    Board director, Shu-Tien Yin Medical Group

    Representative of Corporate Board Director, Renbio Holdings

    Representative of corporate Board director, Renbio, Inc.

    Representative of corporate Board director, Mithra Biotechnology Inc.

    Representative of corporate Board director, Mass Solutions Technology Co., Ltd.

    Representative of corporate Board director, Do-Intelligent Consulting Inc.

    Representative of corporate Board director, Sin-Sheng Biotechnology, Inc.

Mr. Tseng, Tamon LLM. /Director of The Board
  • Current Positions

    Board Director, Tanvex BioPharma, Inc.

    Special Assistant to the CEO of Ruentex Industries, Ltd

  • Previous Experiences

    Mr. Tseng was called to the English Bar in 1985. He received a B.A. from the University of Cambridge, an LL.M. from University College London, and an LL.B. from National Chengchi University.

Mr. Jin Pau Tsai, Independent Director of the Board
  • Current Key Positions

    Independent Director of the Board, Tanvex BioPharma, Inc.

    Board Director, TransGlobal Life Insurance Inc.

    Board Director, Tuntex Incorporation

    Board Director, FCB International Leasing (Suzhou) Co., Ltd.

    Board Director, Orient Recreation and Development Corp.

    Chairman, Jia Guang Enterprise Co., Ltd.

    Chairman, Wan Shi Da Enterprise Co., Ltd.

  • Previous Experiences

    Vice CEO, CEO, Deputy Chairman, PricewaterhouseCoopers, Taiwan

    Vice Chairman, Fuh Hwa Securities Investment Trust Co., LTD.

Mr. Tay-Chang Wang, Independent Director of the Board
  • Current Key Positions

    Professor, Department of Accounting, National Taiwan University

    Independent Director, OBI PHARMA, Inc.

    Independent Director, Gogro Network (Cayman)

    Independent Director, Ruentex Global Co., Ltd.

    Consultant, Taiwan Economic Journal

  • Previous Experiences

    Professor, Department of Accounting, National Taiwan University

Copyright © 2024 Tanvex BioPharma Inc. All rights reserved

Privacy Statement Terms of Use
BACK TO TOP